Company news
Denali Therapeutics Inc. news in 2020
Denali Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.
Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV: IDS (DNL310) in Hunter Syndrome (MPS II)
November 9, 2020
Denali Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
November 4, 2020
Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today
October 14, 2020
Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen
October 6, 2020
Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier
September 29, 2020
Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
August 6, 2020
Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients
August 5, 2020
Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
August 5, 2020
Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients
July 28, 2020
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
June 8, 2020
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
May 26, 2020
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
May 6, 2020
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
April 1, 2020
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
February 26, 2020
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2020
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
January 27, 2020
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
January 13, 2020